Literature DB >> 9798982

Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.

S Raut1, M Di Giambattista, S A Bevan, A R Hubbard, T W Barrowcliffe, R Laub.   

Abstract

The addition of a pasteurisation step to a solvent/detergent (SD) treated FVIII concentrate has recently resulted in enhanced inhibitor incidence in patients in Germany and Belgium. We have investigated the effect of virus inactivation procedures on FVIII function by preparing experimental concentrates from the same starting cryoprecipitate with the following procedures: none (N); dry heat (DH); pasteurisation (P); solvent/detergent (SD); solvent detergent + dry heat (SDDH); solvent detergent + pasteurisation (SDP). In addition, several clinical SD concentrates with and without pasteurisation were studied. There were no significant differences in fibrinogen and vWF content and in the ratio of one-stage/chromogenic FVIII activity among any of the samples studied. In thrombin proteolysis and FXa generation experiments, there were no differences in results on samples N, DH, P, and SDDH from those on sample SD. However sample SDP gave markedly different results from sample SD in the following respects: slower thrombin proteolysis (t(1/2) = 12.0 min vs 1.9 min); more rapid FXa generation (rate 2.5 times that of SD); enhanced phospholipid binding (K(D) = 3.89 x 10(-11) M vs 5.53 x 10(-10) M). Similar differences between SDP and SD were seen in the clinical samples. The observed changes in the FVIII activity occurred in combination with SD and pasteurisation, but not with either treatment alone. These results suggest that SDP treatment may enhance exposure of the phospholipid binding site in the C2 domain of FVIII, and since inhibitors to the SDP product are predominantly against C2, these findings could be relevant to the enhanced immunogenicity of the SDP product.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798982

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

Review 1.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 2.  The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.

Authors:  Rivka Yatuv; Micah Robinson; Inbal Dayan-Tarshish; Moshe Baru
Journal:  Int J Nanomedicine       Date:  2010-09-07

3.  Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.

Authors:  James G Clifton; Feilei Huang; Spomenka Kovac; Xinli Yang; Douglas C Hixson; Djuro Josic
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

4.  A role for thrombin in the initiation of the immune response to therapeutic factor VIII.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Blood       Date:  2009-09-30       Impact factor: 22.113

5.  Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins.

Authors:  Ran Zichel; Wanida Chearwae; Gouri Shankar Pandey; Basil Golding; Zuben E Sauna
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.